200 related articles for article (PubMed ID: 30287186)
1. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.
Kato H; Yamagishi Y; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2019 Apr; 25(4):311-313. PubMed ID: 30287186
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the in Vivo Activities of Garenoxacin and Levofloxacin in a Murine Model of Pneumonia by Mixed-Infection with Streptococcus pneumoniae and Parvimonas micra.
Kato H; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
Jpn J Infect Dis; 2019 Nov; 72(6):407-412. PubMed ID: 31366860
[TBL] [Abstract][Full Text] [Related]
3. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model.
Hagihara M; Kato H; Shibata Y; Sakanashi D; Asai N; Suematsu H; Yamagishi Y; Mikamo H
Anaerobe; 2021 Jun; 69():102346. PubMed ID: 33600958
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.
Okusanya OO; Forrest A; Bhavnani SM; Fernandes P; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182534
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.
Figueira M; Fernandes P; Pelton SI
Antimicrob Agents Chemother; 2016 Sep; 60(9):5533-8. PubMed ID: 27401563
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.
Farrell DJ; Mendes RE; Jones RN
Antimicrob Agents Chemother; 2015 Apr; 59(4):2432-4. PubMed ID: 25605359
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.
Weintraub A; Rashid MU; Nord CE
Anaerobe; 2016 Dec; 42():119-122. PubMed ID: 27725229
[TBL] [Abstract][Full Text] [Related]
9. Results from the Solithromycin International Surveillance Program (2014).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2016 Jun; 60(6):3662-8. PubMed ID: 27044551
[TBL] [Abstract][Full Text] [Related]
10. Solithromycin for the treatment of community-acquired bacterial pneumonia.
Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.
Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P
Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G
Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651
[TBL] [Abstract][Full Text] [Related]
13. The role of solithromycin in the management of bacterial community-acquired pneumonia.
Van Bambeke F; Tulkens PM
Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Oldach D; Clark K; Schranz J; Das A; Craft JC; Scott D; Jamieson BD; Fernandes P
Antimicrob Agents Chemother; 2013 Jun; 57(6):2526-34. PubMed ID: 23507282
[TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M
Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
Kays MB; Lisek CR; Denys GA
Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
